Authorities in Shandong, China approved the methotrexate detection reagent produced by Shandong Oriental Ocean Sci-Tech (SHE:002086) subsidiary Mass Spectrometry Biotechnology, according to a Tuesday filing with the Shenzhen bourse.
The product is used to detect methotrexate levels in human serum or plasma.
Methotrexate is administered during chemotherapy and is an immunosuppressant for autoimmune conditions, the National Institutes of Health said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments